Cases of immune-related nephritis have been reported in cancer patients receiving TECENTRIQ treatment. As of 31 May 2018, there were a total of 28 cases including 13 biopsy confirmed cases in which atezolizumab played a potential role in the development of nephritis. Two of the 28 cases were reported in Canada. Both patients recovered with corticosteroid treatment.
Products affected
TECENTRIQ (atezolizumab), concentrate for solution for infusion, 60 mg / mL in 20 mL single use vials.
Background information
TECENTRIQ has received market authorization in Canada for use in the following clinical settings:
1. Locally Advanced or Metastatic Urothelial Carcinoma TECENTRIQ has been issued marketing authorization with conditions, meaning that that conditions apply, pending the results of studies to verify its clinical benefit for the treatment of patients with
locally advanced or metastatic urothelial carcinoma who:
-
Have disease progression during or following platinum-containing chemotherapy
-
Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy
2. Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) TECENTRIQ has been issued marketing authorization for the treatment of adult patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Immune-related nephritis is defined as renal dysfunction in the absence of alternative etiologies (e.g., prerenal, postrenal causes, or concomitant medications). It is confirmed by biopsy and requires corticosteroid treatment. It is a rare complication of checkpoint inhibitors (CPI) therapy with the most common reported underlying pathology being acute tubulo-interstitial nephritis (ATIN). The most common presentation is asymptomatic increase in creatinine levels.
As of May 31, 2018, a comprehensive analysis of the company clinical safety database, which collects data from various sources such as clinical studies, market research, patient support programs, literature, and post-market studies, identified 28 cases including 13 biopsy confirmed cases in which atezolizumab played a potential role in the development of nephritis. Two of the 28 cases were reported in Canada, but were not biopsy confirmed. Both patients recovered with steroid treatment. An estimated 17,215 and 20,783 patients worldwide have been exposed to TECENTRIQ (atezolizumab) in clinical trial and post-market settings respectively, as of May 17, 2018.